FDA Places Clinical Hold on Tenaya's Gene Therapy Trial for Rare Heart Disease
Key Insights
The FDA has placed a clinical hold on Tenaya Therapeutics' TN-201 gene therapy trial for hypertrophic cardiomyopathy (search) linked to MYBPC3 (search) gene mutations.
The regulatory action requires protocol changes to standardize patient monitoring and immunosuppression drug management, based on previously reviewed safety data.
Despite the hold, Tenaya reports the therapy has been well tolerated with no new safety issues and expects no delays to planned data releases.
The U.S. Food and Drug Administration (search) has placed a clinical hold on Tenaya Therapeutics' experimental gene therapy trial for a rare inherited heart condition, the company announced Friday. The regulatory action sent Tenaya's shares tumbling more than 20% in extended trading.
The early-to-mid stage trial was evaluating TN-201, Tenaya's gene therapy candidate, in patients with hypertrophic cardiomyopathy (search) caused by mutations in the MYBPC3 (search) gene. This rare genetic condition causes abnormal thickening of the heart muscle, which reduces the heart's ability to pump blood effectively.
FDA Requests Protocol Modifications
The FDA's clinical hold centers on requirements for protocol changes to standardize patient monitoring procedures and the management of immunosuppression drugs. These medications are critical components of gene therapy treatment as they help prevent the body's immune system from rejecting the therapeutic intervention.
According to Tenaya, the FDA's decision was based primarily on data that had been previously reviewed by the trial's independent safety board during summer 2025. Notably, that same safety board had concluded that TN-201 demonstrated an acceptable safety profile and had authorized the trial to expand enrollment across two different dose levels.
Safety Profile Remains Favorable
Despite the regulatory hold, Tenaya emphasized that the gene therapy has been generally well tolerated throughout the trial period. The company reported no significant new safety issues have emerged since the summer safety review, suggesting the hold is procedural rather than related to new safety concerns.
"The gene therapy has been generally well tolerated so far, with no significant new safety issues since the summer review," the company stated, adding that it is actively working with the FDA to address the regulatory concerns.
Development Timeline Unchanged
Tenaya indicated it plans to restart patient dosing once the required protocol changes are implemented at trial sites. The company expressed confidence that the clinical hold will not impact its planned data releases or the overall development timeline for TN-201.
The regulatory pause highlights the complex safety considerations involved in gene therapy development, particularly for treatments targeting genetic heart conditions where precise monitoring and immune management protocols are essential for patient safety and treatment efficacy.